Effectiveness of CT‐image guidance in proton therapy for liver cancer and the importance of daily dose monitoring for tumors and organs at risk
Authors: Maeda Yoshikazu , Kobashi Keiji , Sato Yoshitaka , Tamamura Hiroyasu , Yamamoto Kazutaka , Matsushita Keiichiro , Sasaki Makoto , Tatebe Hitoshi , Asahi Tomoko , Matsumoto Sae , Takamatsu Shigeyuki , Miyazaki Koichi , Fujimoto Rintaro , Uchinami Yusuke , Katoh Norio , Aoyama Hidefumi 
Published: April 2023

Background

It is important to have precise image guidance throughout proton therapy in order to take advantage of the therapy's physical selectivity.

Purpose

We evaluated the effectiveness of computed tomography (CT)‐image guidance in proton therapy for patients with hepatocellular carcinoma (HCC) by assessing daily proton dose distributions. The importance of daily CT image‐guided registration and daily proton dose monitoring for tumors and organs at risk (OARs) was investigated.

Methods

A retrospective analysis was conducted using 570 sets of daily CT (dCT) images throughout whole treatment fractions for 38 HCC patients who underwent passive scattering proton therapy with either a 66 cobalt gray equivalent (GyE)/10 fractions (n = 19) or 76 GyE/20 fractions (n = 19) protocol. The actual daily delivered dose distributions were estimated by forward calculation using the dCT sets, their corresponding treatment plans, and the recorded daily couch correction information. We then evaluated the daily changes of the dose indices D99%, V30GyE, and Dmax for the tumor volumes, non‐tumorous liver, and other OARs, that is, stomach, esophagus, duodenum, colon, respectively. Contours were created for all dCT sets. We validated the efficacy of the dCT‐based tumor registrations (hereafter, “tumor registration”) by comparing them with the bone registration and diaphragm registration as a simulation of the treatment based on the positioning using the conventional kV X‐ray imaging. The dose distributions and the indices of three registrations were obtained by simulation using the same dCT sets.

Results

In the 66 GyE/10 fractions, the daily D99% value in both the tumor and diaphragm registrations agreed with the planned value with 3%–6% (SD), and the V30GyE value for the liver agreed within ±3%; the indices in the bone registration showed greater deterioration. Nevertheless, tumor‐dose deterioration occurred in all registration methods for two cases due to daily changes of body shape and respiratory condition. In the 76 GyE/20 fractions, in particular for such a treatment that the dose constraints for the OARs have to be cared in the original planning, the daily D99% in the tumor registration was superior to that in the other registration (p < 0.001), indicating the effectiveness of the tumor registration. The dose constraints, set in the plan as the maximum dose for OARs (i.e., duodenum, stomach, colon, and esophagus) were maintained for 16 patients including seven treated with re‐planning. For three patients, the daily Dmax increased gradually or changed randomly, resulting in an inter‐fractional averaged Dmax higher than the constraints. The dose distribution would have been improved if re‐planning had been conducted. The results of these retrospective analyses indicate the importance of daily dose monitoring followed by adaptive re‐planning when needed.

Conclusions

The tumor registration in proton treatment for HCC was effective to maintain the daily dose to the tumor and the dose constraints of OARs, particularly in the treatment where the maintenance for the dose constraints needs to be considered throughout the treatment. Nevertheless daily proton dose monitoring with daily CT imaging is important for more reliable and safer treatment.